ReviewGut microbes2026
Gut microbiota and immunometabolism in obesity.
Review in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota plays a central role in modulating both immunity and metabolism. Obesity-associated microbiota configuration is a critical driver of persistent inflammatory activation and immune dysfunction, ultimately leading to chronic metabolic disorders. Immunometabolism examines how metabolic demands shape immune cell function and how immune responses influence cellular metabolism. Emerging research on how the gut microbiota contribute to immune cell metabolic processes and the resulting health outcomes is deepening our understanding of the mechanisms underlying obesity and metabolic diseases. In this review, we summarize how intracellular metabolic pathways and master regulators, such as mTOR and AMPK, orchestrate immune cell function and how their dysregulation contributes to obesity-associated immune and metabolic dysfunction. We also discuss how gut microbiota influences the immunometabolism of different myeloid and lymphoid cell subsets and intestinal epithelial cells. Finally, we review the role of microbially produced metabolites, including short-chain fatty acids, lactate, succinate, bile acids, and amino acids, in reprogramming immune cell metabolism. We also discuss whether modulating gut microbiota function to regulate immunometabolic pathways could help restore immune homeostasis and reduce obesity-related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.